Results 231 to 240 of about 444,966 (303)

Bruton tyrosine kinase inhibitors and invasive aspergillosis and mucormycosis: a case report and multi-center exploratory retrospective study. [PDF]

ASM Case Rep
Bhaimia E, Russell D, Santos CAQ.
europepmc   +1 more source

2. Tyrosine Kinase Inhibitors

Nihon Naika Gakkai Zasshi, 2007
openaire   +2 more sources

Dynamic Decoration of DNA Scaffolds for High‐Resolution Cancer Cell Subtyping

Advanced Science, EarlyView.
This study presents a dual‐mode imaging platform that utilizes self‐assembly and disassembly of DNA scaffolds for high‐resolution cancer cell detection. The structural rigidity of DNA scaffolds effectively prevents cellular internalization for over 300 min.
Xiaolin Hu, Jie Xie, Xinlin Guo, Liangting Wang, Zhengheng Yu, Xiaopei Qiu, Heng Li, Kang Wang, Xiaoxing Wang, Mingxuan Song, Junsong Guo, Wei Gu, Sergio Bernardini, Chaoyong Yang, Hong Zhang, Yang Luo   +15 more
wiley   +1 more source

Artificial intelligence modelling of tyrosine kinase inhibitors at risk of malabsorption and bioavailability-enhancing strategies. [PDF]

Br J Clin Pharmacol
Huntjens DW, Béquignon OJM, Krens SD, Löwenberg M, Chamuleau MED, Molenaar RJ, Kramers AMG, Kuijvenhoven MA, Bartelink IH.   +8 more
europepmc   +1 more source

SIRT5–RAC2 Axis Drives Monocyte‐to‐Macrophage Differentiation to Promote Inflammatory Injury in Premature Ovarian Insufficiency

Advanced Science, EarlyView.
SIRT5 desuccinylates and stabilizes RAC2, activating CSF1R‐dependent signaling to drive monocyte differentiation into M0 macrophages and their polarization toward pro‐inflammatory M1 phenotypes in CTX‐induced premature ovarian insufficiency. Inhibiting the SIRT5‐RAC2 axis attenuates inflammation, reduces granulosa cell apoptosis, and preserves ...
Wenjing TanTai, Yaqi Li, Shengnan Liu, Minjuan Wu, Zhixiao Liu, Junfeng Jiang, Jingjing Chen, Xiaoding Xu, Li Li, Chaoqun Li, Fang Zhao, Ye Liu, Haitao Ni, Tengfei Zhang, Mingjuan Xu, Chaofeng Han   +15 more
wiley   +1 more source

Dose Optimization of Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. [PDF]

Clin Pharmacol
Chen J, Zhu Y, Zhao Y, Guo N, Yao Y, Luo X, Huang L.   +6 more
europepmc   +1 more source

Universal Antibody‐Engineered Lipid Nanoparticles Potentiate Chemo‐Immunotherapy Against Triple‐Negative Breast Cancer by Reprogramming Tumor Cell Metabolism

Advanced Science, EarlyView.
A universal ROR1 antibody‐engineered lipid nanoparticle (LNP) is constructed by sequential drug encapsulation and antibody conjugation. The LNP not only enables enhanced chemotherapeutic efficiency by targeting drug delivery and precise localization of deep‐seated tumors through NIR‐II fluorescence imaging, but also remodels immunosuppressive TME ...
Yeneng Dai, Jiaqi Wang, Yu Liu, Guanda Jiao, Yuheng Gu, Yang Liu, Shengyu Fu, Xing Fan, Jialin Li, Ziang Guo, Kam Tong Leung, Lipeng Zhu, Qi Zhao   +12 more
wiley   +1 more source

Using a Novel Consensus-Based Chemoinformatics Approach to Predict ADMET Properties and Druglikeness of Tyrosine Kinase Inhibitors. [PDF]

Int J Mol Sci
Mavridis E, Hadjipavlou-Litina D.
europepmc   +1 more source

Cytokine‐Engineered Chimeric Antigen Receptor‐T Cell Therapy: How to Balance the Efficacy and Toxicity

Advanced Science, EarlyView.
Cytokine‐engineered CAR‐T cells represent a promising immunotherapy against malignancies due to direct tumor killing and potent immunity response. However, significant toxicities, including CRS and ICANS, have restricted clinical applications. How to keep the risk‐benefit balance of the advanced therapy is of great importance for maximizing the benefit
Xinru Zhang, Gulizeba Aimaiti, Yuanye Guan, Yuzhe Sha, Wei Zhou, Jiefeng Shen, Bo Zhao, Wei‐En Yuan   +7 more
wiley   +1 more source

Cardiovascular Safety of Bruton Tyrosine Kinase Inhibitors: From Ibrutinib to Next-Generation Agents. [PDF]

Am J Cardiovasc Drugs
Spadafora L, Russo F, Bukowska-Olech E, Panichella G, Garofalo M, Cacciatore S, Sabouret P, Sarto G, Simeone B, Rocco E, Lauretti A, Versaci F, Zoccai GB, Colaiori I, Valenti V, Sciarretta S, Bernardi M.   +16 more
europepmc   +1 more source